Moneycontrol » News » Business » Business News

Orchid receives US FDA approval for Cefuroxime Axetil ANDA

Published on Wed, Feb 20, 2008 at 11:59 |  Source : Moneycontrol.com

Updated at Wed, Feb 20, 2008 at 13:05  

24401 Investors following Orchid Chemical. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

Orchid Chemical

BSE | NSE 10/02/12

The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid) today announced that it has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Cefuroxime Axetil Tablets. The product is available in three dosage strengths, 125 mg, 250 mg and 500 mg.

 

This is the 25th ANDA approval that Orchid has received since it started its US Generics journey in 2005.

  

Sourced From: Orchid Chemicals & Pharmaceuticals Ltd

  

PREVIOUS STORY

To claim or not to claim - The HRA and Home loan dilemma!

NEXT STORY

Numeric Power Systems sells UPS business for Rs 837 cr

More on Moneycontrol
Headlines
view all »
S&P downgrades 34 Italian banks
01:36 AM
S&P downgrades 34 Italian banks
The week that was: Deal or no deal, mkt in for taxing times
07:47 PM
The week that was: Deal or no deal, mkt in for taxing times
Know Your Investment: Expert takes 'stock' of your stocks!
08:36 PM
Know Your Investment: Expert takes 'stock' of your stocks!
Wall St week ahead: Bulls won't be tamed by weak earnings
04:52 AM
Wall St week ahead: Bulls won't be tamed by weak earnings
Video of the day
'5200 strong support for mkt, next resistance at 5500-5550'
play
09:56 AM
'5200 strong support for mkt, next resistance at 5500-5550'
- in FII View
Sensex logs 6th week of gain, ends day with 85 pts loss
Listen Now!
Slideshows

Trending News

Business News

Tags: Orchid Chemicals & Pharmaceuticals, ANDA , Cefuroxime Axetil Tablets, dosage
No entry fee to migrate to Unified License, proposes TRAI
Rupee rally may stall with fall against US dollar, euro "Rupee rally may stall with fall against US dollar, euro"

News

Sources Say 'Meet To Decide If Govt Should Move Leave Plea On SC Order'

The latest earning numbers FIRST on CNBC-TV18
Videos

Feb 10 2012, 21:39

Tulsian buys steel stocks; negative on sugar, ADAG

- in MARKET OUTLOOK

Feb 10 2012, 21:39

Truck demand sluggish; margins down 80bps: Shriram Trans

- in Results Boardroom

Interviews

Feb 10 2012, 15:43 | Source: CNBC-TV18

Growth in margins sustainable going forward: Shasun Pharma  

Feb 10 2012, 15:35 | Source: CNBC-TV18

Expect Q4 GRMs to be similar to Q3: BPCL  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!

Follow moneycontrol.com

Explore Moneycontrol

STOCKS     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
MUTUAL FUNDS     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
News | Markets | IPO | Technicals | Mutual Fund | Commodities | Best Portfolio Manager | Bse Sensex | Bombay Stock Exchange | Share Market Live | Commodities Price | Silver Price/Rate in India | Gold Price/Rate in India | Crude Oil | USD to INR | National Stock Exchange | Bank Fixed Deposits | Company Fixed Deposits | Small Savings Schemes | Bonds | Unit Linked Insurance Plans (ULIPs) | | Budget: 2008, 2009, 2010, 2011, 2012 |  Intuit Money Manager | RBI Credit Policy | Union Budget | Budget 2012  | Economic Survey  | Railway Budget  | Financial Glossary  |  Message Board | Moneybhai | Connect.in.com | Business Yellow Pages | India's Premiere Technology Guide | History India  | Up Polls |  Latest News  | Uninor | Tata Steel | BSE Sensex | Commodities | Aurobindo Pharma | Namma Metro | Mahindra Satyam | Iran | Reliance Industries | Vodafone Essar
Site Map  |  About Us  |  Contact Us  |  Advertise  |  Bookmark  |  Disclaimer  |  Privacy Statement  |  Terms of Use  |  Careers
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.